stockrow
Friday 6 November 2026
Export IMVT’s income statement to Excel — free account
Immunovant, Inc.
IMVT Healthcare Biotechnology
- EPS
- −5.63%
- Free cash flow
- −5.96%
Quarter to June 2026, against a year earlier
30.53
2.14
+7.54%
Follow IMVT
Alert me
Immunovant, Inc. (IMVT) P/E ratio
Immunovant, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | n/m |
| MIRM Mirum Pharmaceuticals, Inc. compare | n/m |
| CGON CG Oncology, Inc. compare | n/m |
| MANE Veradermics Incorporated compare | n/m |
| IMVT Immunovant, Inc. | n/m |
| IONS Ionis Pharmaceuticals, Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | n/m |
| KOD Kodiak Sciences Inc. compare | n/m |
| LGND Ligand Pharmaceuticals Incorporated compare | 116× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)